This study is to evaluate the efficacy and safety of the Jinghua Weikang Capsule (a Chinese patent medicine for peptic ulcer and gastritis) containing quadruple therapy (Jinghua Weikang Caplsule plus triple therpy) for eradicating Helicobacter pylori in IgA nephropathy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
80
Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and Jinghua Weikang Capsule 240mg twice daily for 14 days.
Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and bismuth potassium citrate 220mg twice daily for 14 days.
Peking University First Hospital
Beijing, Beijing Municipality, China
Helicobacter pylori eradicaion rate
The Helicobacter pylori infection status was measured by 13-carbon breath test.
Time frame: The forth week after the treatment.
Blood creatinine level
The change of average blood creatinine level between two groups.
Time frame: Baseline, the third and sixth month after the treatment, respectively.
Blood urea nitrogen level
The change of average blood urea nitrogen level between two groups.
Time frame: Baseline, the third and sixth month after the treatment, respectively.
eGFR
The change of average eGFR level between two groups.
Time frame: Baseline, the third and sixth month after the treatment, respectively.
24hrs urine protein level
The change of average24hrs urine protein level between two groups.
Time frame: Baseline, the third and sixth month after the treatment, respectively.
Blood presure
The change of average blood presure level between two groups.
Time frame: Baseline, the third and sixth month after the treatment, respectively.
IgA level
The change of average IgA level level between two groups.
Time frame: Baseline, the third and sixth month after the treatment, respectively.
IgA1 level
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The change of average IgA1 level between two groups.
Time frame: Baseline, the third and sixth month after the treatment, respectively.
Gd-IgA1 level
The change of average Gd-IgA1 level level between two groups.
Time frame: Baseline, the third and sixth month after the treatment, respectively.